Kerusso Capital Management LLC Purchases 12,988 Shares of Bristol Myers Squibb Company $BMY

Kerusso Capital Management LLC boosted its position in Bristol Myers Squibb Company (NYSE:BMY) by 23.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,527 shares of the biopharmaceutical company’s stock after acquiring an additional 12,988 shares during the quarter. Kerusso Capital Management LLC’s holdings in Bristol Myers Squibb were worth $3,642,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. WPG Advisers LLC increased its stake in Bristol Myers Squibb by 36.1% in the fourth quarter. WPG Advisers LLC now owns 1,768 shares of the biopharmaceutical company’s stock valued at $95,000 after acquiring an additional 469 shares during the last quarter. Chicago Partners Investment Group LLC increased its stake in Bristol Myers Squibb by 84.8% in the fourth quarter. Chicago Partners Investment Group LLC now owns 43,897 shares of the biopharmaceutical company’s stock valued at $2,399,000 after acquiring an additional 20,140 shares during the last quarter. Schmidt P J Investment Management Inc. bought a new position in Bristol Myers Squibb in the fourth quarter valued at $202,000. Turtle Creek Wealth Advisors LLC boosted its position in Bristol Myers Squibb by 79.4% during the fourth quarter. Turtle Creek Wealth Advisors LLC now owns 8,775 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 3,885 shares during the period. Finally, waypoint wealth counsel purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at about $1,194,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $59.02 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm has a 50-day moving average of $59.72 and a 200-day moving average of $53.99. The firm has a market cap of $120.50 billion, a P/E ratio of 17.11, a P/E/G ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.28 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays upgraded BMY to a Buy, which can support the stock by drawing investor interest and providing a catalyst for further upside. Read More.
• Positive Sentiment: Atrium Therapeutics announced it earned a $15 million development milestone payment from Bristol Myers Squibb under a global cardiovascular collaboration — a signal that a partnered program has hit a development milestone, de‑risking part of BMY’s external pipeline (though it represents a cash outflow). Read More.
• Positive Sentiment: Positive coverage pieces highlighting BMY as a momentum/long‑term holding can attract buy‑and‑hold investors and support multiple expansion. Read More.
• Neutral Sentiment: BMY is a counterparty on a corporate PPA: a new solar project will supply power through previously signed PPAs that include Bristol Myers Squibb — a modest ESG/operational positive but unlikely to move the stock materially. Read More.
• Neutral Sentiment: Industry market reports (vulvar cancer, Sjögren’s syndrome) mention Bristol Myers Squibb among major players — useful context on addressable markets but not an immediate stock driver. Read More. | Read More.
• Neutral Sentiment: Bristol Myers Squibb is expected to report quarterly earnings this week — the timing itself is a catalyst but the direction depends on results and guidance. Read More.
• Negative Sentiment: Analyst previews from Yahoo/Zacks flag that BMY currently lacks the “right combination” of factors (revenue mix and margin tailwinds) that typically produce an earnings beat; consensus calls for a decline in EPS, heightening the risk of a negative market reaction if results disappoint. Read More.
• Negative Sentiment: Bernstein maintained a Hold on BMY, a cautious stance that can cap upside from upgrades and keeps some investors sidelined. Read More.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. HSBC upped their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Scotiabank restated a “sector perform” rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Guggenheim restated a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Sunday, April 19th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Eight research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.